Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer

✍ Scribed by D. J. Perez; T. J. Powles; J. -C. Gazet; H. T. Ford; R. C. Coombes

• Publisher: Springer
• Year: 1984
• Tongue: English
• Weight: 299 KB
• Volume: 13
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/bf00401444

✦ Synopsis

Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen. Of 48 evaluable patients 19 (40%) responded for a median period of 5 months and 12 (25%) had stabilisation of disease. Of the 12 patients previously treated with adriamycin only one responded, whereas 18 of the 36 patients without previous chemotherapy responded. Although healing of bone metastases was infrequent control of hypercalcaemia was commonly seen. Generally the treatment was well tolerated and treatment was stopped in only five patients because of toxicity. Cumulative marrow toxicity was observed but was not a significant problem in the first 6 months of treatment. Mitomycin C, melphalan, and methotrexate (MMM) appears to provide an effective, well tolerated chemotherapy combination for metastatic breast carcinoma.